NeuroQuant

by Cortechs.ai  · Based in United States → — AI-powered precision to optimize patient care. Quantitative imaging insights for neurological and oncological disease.
Neurology Oncology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Subscription-based, with pricing based on the number of analyses and/or installations.
Regulatory Status Disclosed

Overview

NeuroQuant by CorTechs Labs (also known as Cortechs.ai) is a fully automated advanced imaging software designed for comprehensive brain MRI segmentation and volumetric quantification. This AI-powered medical device aids physicians in the detection, diagnosis, and monitoring of a wide range of neurological conditions by providing objective, quantitative data on brain structure volumes and lesion analysis.

The software integrates seamlessly into radiology workflows, offering fast and accurate analysis of 3D T1 MRI scans, and optionally T2 FLAIR and T2* GRE/SWI series for lesion quantification. NeuroQuant compares individual patient brain structure volumes to a unique normative database, which includes data from healthy individuals aged 3 to 100, normalized for age, gender, and intracranial volume.

Key functionalities include longitudinal tracking to assess changes in brain structure volumes and lesions over time, customizable volumetric reports, and advanced capabilities for segmenting and quantifying Amyloid-Related Imaging Abnormalities (ARIA) in Alzheimer’s patients, as well as various brain tumors.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Fully automated brain segmentation and volumetric analysis
  • Quantitative 3D T1 MRI post-processing image analysis
  • Comparison to normative database (ages 3-100, age/gender matched)
  • Longitudinal tracking of brain structure volumes and lesion changes over time
  • Detection and quantification of ARIA-E and ARIA-H
  • Segmentation and quantification of brain lesions (T2 FLAIR hyperintense, T2* GRE/SWI hypointense)
  • Customizable volumetric reports
  • Seamless integration into PACS systems
  • Cloud-based AI software
  • Supports data from all major MRI manufacturers

Use Cases

  • Assessment of neurodegenerative diseases (e.g., Alzheimer's, other dementias)
  • Monitoring Multiple Sclerosis (MS) progression and treatment
  • Evaluation of Traumatic Brain Injury (TBI)
  • Diagnosis and assessment of epilepsy
  • Quantification of brain tumors (gliomas, metastases, meningiomas)
  • Assessment of brain development abnormalities

What Physicians Need to Know

Brain MRI/CT Analysis
NeuroQuant offers automated volumetric MRI analysis, segmenting and quantifying brain structures from 3D MRI images and comparing them to a normative database. It supports various neurological conditions including Alzheimer's disease, epilepsy, TBI, and multiple sclerosis. NeuroQuant CT provides automated post-processing for head CTs, calculating midline shift index and offering volumetric analysis of lateral ventricles and total intracranial volume. It also registers head CT images to an anatomical atlas for standardized viewing and generates subtraction maps. NeuroQuant PET automates brain PET analysis by segmenting anatomical regions from a patient's MRI, measuring tracer uptake, and comparing values against normative data, providing SUVRs and Centiloid quantification for amyloid PET.
Seizure Detection
NeuroQuant Seizure quantifies hippocampal volume and asymmetry, providing objective insights for diagnosing and treating epilepsy. It measures the size difference between left and right hippocampi, which can indicate structural changes due to epilepsy. The tool aids in identifying structural changes contributing to seizures, tailoring treatment plans, and monitoring disease progression. NeuroQuant's Hippocampal Asymmetry report provides volume measurements of the left and right hippocampus, their asymmetry, and compares them to a healthy population.
Neurodegenerative Disease Screening
NeuroQuant is designed to segment, quantify, and compare brain structure volume for neurodegenerative diseases, aiding in early detection and assessment. It provides objective, volumetric data and color-coded brain structure analysis to support clinical impressions. Reports like the Age-Related Atrophy Report quantify neurodegeneration of the hippocampus and inferior lateral ventricles for conditions like Alzheimer's disease. The Microvascular Report quantifies white matter hyperintensities and automates Fazekas scoring for assessing vascular contributions to cognitive decline. NeuroQuant PET provides objective, reproducible quantification for amyloid and metabolic brain imaging, supporting the assessment of cognitive impairment.
Triage Prioritization Speed
NeuroQuant CT aims to improve workflow efficiency and radiologist productivity by providing consistent views of head CT exams and automated quantitative measurements. NeuroQuant's automated analysis can detect subtle atrophic changes that might be missed by visual assessment, potentially leading to faster identification of issues.
Physician Tip

NeuroQuant provides objective, quantitative data that can supplement visual assessments of MRI and CT scans, enhancing diagnostic confidence and reducing inter-reader variability. Utilizing the various NeuroQuant reports (e.g., Dementia, Seizure, Microvascular, Triage Brain Atrophy) can help tailor the analysis to specific clinical questions and conditions. The ability to track changes over time with longitudinal analysis is crucial for monitoring disease progression and treatment effectiveness in neurodegenerative conditions and epilepsy. Custom reports allow physicians to focus on specific brain structures relevant to less common or complex neurological disorders. Ensure that MRI scans adhere to recommended protocols for optimal NeuroQuant processing and accurate results.

Cortechs.ai has strategic partnerships to integrate NeuroQuant into various platforms and ecosystems. It is integrated with Viz.ai's platform to expand access to quantitative neuroimaging for hospitals and health systems. NeuroQuant Lesion Surveillance is integrated and distributed through the Siemens Healthineers Digital Marketplace. Cortechs.ai collaborates with Microsoft to integrate its solutions, including the NeuroQuant platform, into PowerScribe One and the broader Microsoft ecosystem for seamless workflow integration and enhanced reporting. NeuroQuant is also available through CARPL.ai's radiology AI marketplace and enterprise imaging AI platform, expanding global access to these tools.

Details

Category Neurology AI
Pricing Subscription-based, with pricing based on the number of analyses and/or installations.
DeploymentCloud-based, stand-alone third-party application, or stand-alone web-based.
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated
SOC 2 Yes AI-estimated
GDPR Yes AI-estimated
Integrations
EHR Not specified
Specialties Neurology, Oncology, Radiology

Support & Reliability

What the Web Says

NeuroQuant is an FDA-cleared software that provides precise volumetric measurements of brain structures from standard MRI images, aiding in the diagnosis and monitoring of neurological conditions like Alzheimer's disease, multiple sclerosis, and traumatic brain injury. Physicians and neurologists find it an essential tool for objective, data-driven neurological care, enhancing diagnostic accuracy and treatment planning. It helps detect subtle brain changes earlier than visual assessment alone, providing quantitative data that is highly valued by clinicians.

Overall: Positive

Strengths

  • Provides objective, quantitative measurements of brain structures, reducing subjectivity in diagnosis.
  • Aids in earlier detection and more accurate diagnosis of various neurological conditions.
  • Helps in monitoring disease progression and treatment effectiveness over time.
  • Validated against gold-standard research methods like FreeSurfer, showing high reliability and accuracy.
  • Streamlines workflow and improves efficiency by processing scans quickly and producing standardized reports.
  • Offers valuable insights for referring neurologists and improves communication of findings to patients.

Limitations

  • The user interface can be intimidating initially and requires time to get used to.
  • Segmentation errors can occur, necessitating visual inspection of results for verification.
  • Some medical professionals may be dismissive or unfamiliar with the technology.
  • Radiologists may not always include NeuroQuant abnormalities in their reports, even when present.

Based on reviews from: americanhealthimaging.com, cortechs.ai, elion.health, nih.gov, youtube.com, reddit.com, milleniummri.com, neurology.org, capterra.com, g2.com

Last updated: 2026-10-29

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate NeuroQuant

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

cortechs.ai
Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment
Cortechs.ai announced FDA 510(k) clearance for NeuroQuant® PET, a software designed to aid physicians in evaluating patient pathologies and interpreting PET scans for cognitive impairment and other neurological conditions. This clearance allows for automated quantification, regional analysis, and structured reporting of PET imaging data, supporting precision medicine in Alzheimer's disease and related dementias.
2026-08
medpath.com
FDA Clears Cortechs.ai's NeuroQuant PET - Imaging Technology News
Cortechs.ai's NeuroQuant PET received FDA 510(k) clearance (K261916) for automated quantification and clinical interpretation of PET imaging in cognitive impairment and other neurological conditions. The platform provides atlas-based quantification of amyloid PET tracers, generating SUVRs and Centiloids for flutemetamol, florbetaben, and florbetapir to enable standardized cross-tracer comparison.
2026-08
auntminnie.com
Cortechs.ai wins FDA clearance for NeuroQuant PET
Cortechs.ai has received U.S. Food and Drug Administration 510(k) clearance for NeuroQuant PET, an automated quantification platform for amyloid PET imaging in Alzheimer's disease and other neurological conditions. The software generates structured reports of standardized uptake value ratios (SUVRs) and Centiloid measurements for various amyloid PET tracers, enabling standardized comparison across tracers and imaging systems.
2026-08
cortechs.ai
Cortechs.ai Expands European CE Marking Across AI Imaging Platform, Accelerating Global Growth
Cortechs.ai announced the expansion of its European CE Marking under the EU MDR for its latest imaging products, including NeuroQuant® (featuring NeuroQuant®, NeuroQuant® MS, and NeuroQuant® ARIA), NeuroQuant® Brain Tumor, and OnQ™ Prostate. This certification reinforces the company's commitment to delivering innovative imaging solutions worldwide and establishes a foundation for continued platform expansion across Europe.
2026-08
cortechs.ai
Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies
Cortechs.ai announced a strategic partnership with Siemens Healthineers to integrate and distribute NeuroQuant® Lesion Surveillance through the Siemens Healthineers Digital Marketplace. This collaboration aims to accelerate the worldwide adoption of quantitative brain imaging, improving diagnostic precision and optimizing clinical workflows, particularly for complex dementia care pathways.
2026-03
cortechs.ai
Cortechs.ai Announce Next-Gen NeuroQuant Brain Tumor: AI-Driven Metastasis & Meningioma Segmentation
Cortechs.ai announced the immediate availability of its latest release of the FDA-cleared NeuroQuant® Brain Tumor, which now offers fully automated segmentation and volumetric reporting of brain metastases and meningiomas. This AI-powered solution aims to enhance radiologists', neurosurgery, and neuro-oncology efficiency and standardization by delivering objective segmentations and volumetric reports.
2025-07
cortechs.ai
Cortechs.ai Announces Major FDA 510(k)-Pending Update to NeuroQuant Software
Cortechs.ai announced a major update for its flagship product, NeuroQuant® v5.0, which is currently FDA 510(k) pending. This update will expand the software's use to support the identification and evaluation of cerebral microhemorrhages on susceptibility-sensitive MRI sequences, commonly found in patients with Traumatic Brain Injuries (TBI), Cerebral Amyloid Deposition Diseases, and Amyloid Related Imaging Abnormalities (ARIA).
2024-04
cortechs.ai
Cortechs.ai and CARPL.ai Partner to Expand Global Access to AI-Powered Imaging Solutions
Cortechs.ai announced a strategic partnership with CARPL.ai, the world's largest radiology AI marketplace, to make Cortechs.ai's suite of advanced AI imaging solutions, including various NeuroQuant® products, more accessible to healthcare organizations. This collaboration aims to integrate these applications into existing clinical workflows, enabling radiologists and clinicians to leverage advanced quantitative imaging insights seamlessly.
2026-10

Videos

Product demos, reviews, and walkthroughs for NeuroQuant.

View all on YouTube

Frequently Asked Questions

NeuroQuant is an FDA-cleared software that analyzes brain MRI images to provide precise volumetric measurements of brain structures. It helps physicians detect and track subtle brain changes associated with neurological conditions like dementia, Alzheimer's disease, multiple sclerosis, traumatic brain injury, and epilepsy, often earlier than visual inspection alone. It compares an individual's brain structure volumes to a normative database matched for age, sex, and cranial size to identify abnormalities.
While powerful, NeuroQuant has limitations. Not all healthcare facilities have access to the technology, and there's a learning curve for interpreting reports. The software requires specific MRI acquisition protocols (T1, sagittal, non-contrast, 3D) for optimal results, and deviations can reduce quality. Artifacts like shunts, implants, or excessive cranial tissue can prevent accurate analysis. Additionally, while AI assists in diagnosis, the physician's role in interpreting data and making treatment decisions remains crucial.
NeuroQuant is FDA-cleared and CE marked, demonstrating compliance with health, safety, performance, and environmental protection requirements. The software automatically checks MRI data parameters to ensure accurate collection, rejecting submissions that don't meet criteria for FDA compliance. It also undergoes rigorous verification and validation testing to ensure it meets functionality requirements and clinical expectations. The normative database is regularly updated to ensure accuracy and sensitivity to subtle changes.
Several other FDA-cleared brain volumetrics software products exist, including icometrix icobrain (now GE HealthCare), Quantib ND (RadNet), Combinostics cNeuro, Neurophet AQUA, and Neuroreader (Brainreader). While these alternatives offer similar functionalities, they may differ in their specific focus, such as ARIA grading for anti-amyloid therapy patients or multimodal dementia work.
CorTechs Labs offers NeuroQuant modules under an unlimited subscription model rather than per-study pricing. This means an organization licenses the technology, and eligible examinations are processed without an additional charge for each analysis, making costs predictable regardless of utilization. This contrasts with per-analysis models where each case presents a small financial question before a clinical one.

Compare NeuroQuant

VS
NeuroQuant vs JLK-SDH
Neurology AI Adjacent · 65/100
NeuroQuant provides comprehensive, quantitative volumetric analysis of brain MRI for a broad spectrum of neurological and oncological conditions, focusing on detailed assessment and longitudinal monitoring. Conversely, JLK-SDH is…
VS
NeuroQuant vs OnQ Neuro
Neurology AI Adjacent · 75/100
NeuroQuant offers broad brain MRI volumetric analysis for neurodegenerative diseases, trauma, and general lesions, including comparisons to normative data. OnQ Neuro, while also from CorTechs Labs, specializes in…

Related Tools

Parkiwatch
Koios Care
Neurology AI
Parkiwatch by Koios Care is a Class IIa Software as a Medical Device (EU MDR 2017/745) for continuous, passive detection and quantitative assessment of kinematic patterns representative of tremor, bradykinesia, and dyskinesia in adults with Parkinson's Disease.
Paid
CortiCare (Virtual EEG Department)
CortiCare
Neurology AI
CortiCare offers 24/7 remote EEG monitoring and interpretation services, functioning as a virtual EEG department to assist hospitals and neurology practices in identifying seizures and other neurological conditions.
NeuroAstra
Avinya NeuroTech
Clinical Decision Support & Reference
NeuroAstra is an AI-enabled EEG analysis and reporting software that provides a multimodal clinical EEG web platform with Co-Pilot AI to help neuro care teams detect abnormal trends faster and standardize reporting.
Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
CoLumbo C-Spine
Smart Soft Healthcare AD
Clinical Decision Support & Reference
CoLumbo C-Spine is an AI-powered software that processes and analyzes cervical spine MRI exams, assisting clinicians in diagnosis and assessment.
MeRT System
Wave Neuroscience
Mental & Behavioral Health AI
MeRT (Magnetic e-Resonance Therapy) is an advanced, personalized form of TMS that uses your own brainwave data to guide treatment. It's a non-invasive, drug-free option designed to help the brain communicate more efficiently so symptoms of conditions like depression, anxiety, PTSD, TBI, autism, and more can improve.
Paid

See all Neurology AI tools →

More from Cortechs.ai

RSI-MRI+
Cortechs.ai
Oncology AI
RSI-MRI+ is an FDA-cleared AI-powered imaging software by HealthLytix (now CorTechs Labs) that uses Restriction Spectrum Imaging (RSI) to enhance the detection and diagnosis of prostate cancer through improved visualization and quantification of restricted water in MRI scans.

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.